P
Pascal Jézéquel
Researcher at University of Nantes
Publications - 76
Citations - 4006
Pascal Jézéquel is an academic researcher from University of Nantes. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 26, co-authored 68 publications receiving 3305 citations. Previous affiliations of Pascal Jézéquel include Centre national de la recherche scientifique & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau,Christophe Le Tourneau,Jean Pierre Delord,Anthony Gonçalves,Céline Gavoille,Coraline Dubot,Nicolas Isambert,Mario Campone,Ol vier Trédan,Marie Ange Massiani,Cecile Mauborgne,Sebastien Armanet,Nicolas Servant,Ivan Bièche,Virginie Bernard,David Gentien,Pascal Jézéquel,Valéry Attignon,Sandrine Boyault,Anne Vincent-Salomon,Vincent Servois,Marie Paule Sablin,Maud Kamal,Xavier Paoletti,Xavier Paoletti +24 more
TL;DR: The efficacy of several molecularly targeted agents marketed in France, which were chosen on the basis of tumour molecular profiling but used outside their indications, in patients with advanced cancer for whom standard-of-care therapy had failed is assessed.
Journal ArticleDOI
Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
Olivier Decaux,Laurence Lodé,Florence Magrangeas,Catherine Charbonnel,Wilfried Gouraud,Pascal Jézéquel,Michel Attal,Jean-Luc Harousseau,Philippe Moreau,Régis Bataille,Loïc Campion,Hervé Avet-Loiseau,Stephane Minvielle +12 more
TL;DR: Gene expression-based survival prediction and molecular features associated with high-risk patients may be useful for developing prognostic markers and may provide basis to treat these patients with new targeted antimitotics.
Journal ArticleDOI
Haemochromatosis and HLA–H
Anne-Marie Jouanolle,G. Gandon,Pascal Jézéquel,Blayau M,Campion Ml,J. Yaouanq,Jean Mosser,Patricia Fergelot,Bruno Chauvel,Pascale Bouric,Gwenaelle Carn,Nancy Andrieux,Isabelle Gicquel,Le Gall Jy,David +14 more
Journal ArticleDOI
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer.
Pascal Jézéquel,Mario Campone,Wilfried Gouraud,Catherine Guérin-Charbonnel,Christophe Leux,Gabriel Ricolleau,Loïc Campion +6 more
TL;DR: The aim was to develop a user-friendly, web-based application, based on DNA microarrays results, called “breast cancer Gene-Expression Miner” (bc-GenExMiner) to improve gene prognostic analysis performance by using the same bioinformatics process.
Journal ArticleDOI
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response
Pascal Jézéquel,Delphine Loussouarn,Catherine Guérin-Charbonnel,Loïc Campion,Antoine Vanier,Wilfried Gouraud,Hamza Lasla,Catherine Guette,Isabelle Valo,Véronique Verriele,Mario Campone +10 more
TL;DR: It is shown that macrophages and other immune effectors offer a variety of therapeutic targets in breast cancer, and particularly in triple-negative basal-like tumours, and that CK5 antibody was better suited than CK5/6 antibody to subtype triple- negative patients.